1QBit has announced the launch of 1QBit xrAI, a chest radiography AI tool that significantly improves the accuracy and timeliness of diagnosing lung abnormalities.
The company’s first healthcare product received expedited Health Canada approval in just one week following its recently completed extensive clinical trials.
1QBit employs physicians, biomedical experts, mathematicians, computer scientists, physicists, chemists, software developers, and other quantum computing specialists. The Vancouver-based company develops novel solutions to computational problems along the full stack of quantum computing, from hardware innovations to commercial application development.
Within days of this regulatory approval, the Saskatchewan Health Authority has plans to go-live with the new tool to help combat COVID-19.
“We have been working on this artificial intelligence product for two years and the launch could not come at a better time for Canada and the world as we battle COVID-19,” said Deepak Kaura, Chief Medical Officer of 1QBit and a practicing pediatric radiologist.
“Unlike other image recognition software solutions that are created by technology companies first and then sold to medical professionals, xrAI has been researched and developed by clinicians. In my experience building health services domestically and internationally, I am inspired by the Canadians who have accelerated the clinical trials, overseen stringent regulatory processes, and who are now willing to implement xrAI such that it impacts patients so quickly.”
xrAI can be deployed on classical processors in the cloud or on-premise, helping clinicians better identify patients with respiratory complications including SARS, pneumonia, tuberculosis, and other abnormalities. In evaluating publicly available data of COVID-19 pneumoniae, 1QBit xrAI accurately identified 100% of cases with pulmonary abnormalities.
1QBit raised a $45 million Series B financing round led by Fujitsu in 2017.